Boston, MA 06/04/2014 (wallstreetpr) – Prosensa Holding NV (NASDAQ:RNA) on June 3, 2014 publicized the news that the U.S. Food and Drug Administration (FDA) has showed a sight of a positive signal for the company’s most advanced muscle disorder drug.
Prosensa On The Right Track To Bring Muscle Disorder Drug:
The drug is aimed to treat patients suffering from the muscle disorder. The Netherland based medical company; Prosensa Holding NV (NASDAQ:RNA) on Tuesday, June 3, 2014 stated that it is planning to perform two more studies and will apply to the U.S. marketing for at the end of this year. However, the company will also ask for European approval in some years, stated the company.
Drug May Win The U.S. Approval By 2015:
An analyst of KBC Securities, Jan De Kerpel commented that Prosensa’s medicine to treat DMD (Duchene muscular dystrophy) may snatch the U.S. sanction in 2015, similarly like Sarepta Therapeutics Inc’s Eteplirsen drug. Moreover, the drug can also fetch huge amount of sales of almost $1.36 billion and rank itself among the topmost medicine in muscular disorder issues. However, the company has to pay 200,000 Euros every year for patent. The analyst also added that the treatment of Prosensa Holding NV (NASDAQ:RNA) will gain better appreciation than Sarepta’s drug.
Cause Of Muscle Disorder:
DMD is caused due to insufficient production of a protein called dystrophic; the drug is designed in such a way which will augment the production of that very protein inside the body. In recent months, the drug has received tremendous positive signals from the regulators. The company in the month of January announced that despite of few failures in producing the drug, Prosensa will carry out the research work to ensure the successful completion of drisapersen.
At the beginning of this month, GlaxoSmithKline Plc, partnered with Prosensa Holding NV (NASDAQ:RNA) gave the right to the company, ending the 2009 collaboration agreement. However, the company now needs to focus more on trials in order to make the drug a successful one.
